M

MedPacto Inc
KOSDAQ:235980

Watchlist Manager
MedPacto Inc
KOSDAQ:235980
Watchlist
Price: 6 520 KRW -2.4% Market Closed
Market Cap: 223.5B KRW
Section:
 

Relative Value

The Relative Value of one MedPacto Inc stock under the Base Case scenario is 448.71 KRW. Compared to the current market price of 6 520 KRW, MedPacto Inc is Overvalued by 93%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
448.71 KRW
Overvaluation 93%
Relative Value
Price
M
Worst Case
Base Case
Best Case

Valuation Multiples

90.5
P/S
P/S
Price to Sales
90.5
vs History
12
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.2
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-9.9
Median 5Y
-13.8
Industry
24.2
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-11.7
Median 5Y
-17.3
Industry
23
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-9.2
Median 5Y
-9.2
Industry
25.5
More Details
4.6
P/B
P/B
Price to Book Value
4.6
vs History
69
vs Industry
41
Median 3Y
4.7
Median 5Y
10.7
Industry
3.3
More Details
73.4
EV/S
EV/S
Enterprise Value to Sales
73.4
vs History
6
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.6
More Details
824
EV/GP
EV/GP
Enterprise Value to Gross Profit
824
vs History
1
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.5
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-7.5
Median 5Y
-12.8
Industry
6.1
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-6.9
Median 5Y
-11.8
Industry
6.6
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-8.1
Median 5Y
-14.6
Industry
8.8
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-8.1
Median 5Y
-14
Industry
6.8
More Details
22.8
EV/IC
EV/IC
Enterprise Value to IC
22.8
vs History
68
vs Industry
25
Median 3Y
23.5
Median 5Y
36.6
Industry
5.7
More Details

Multiples Across Competitors

Competitors Multiples
MedPacto Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
MedPacto Inc
KOSDAQ:235980
223.5B KRW 90.5 -15.3 -12.4 -11.4
IL
Can Fite Biopharma Ltd
TASE:CANF
154.4T ILS 56 284 545.2 -3 865 260.4 -3 793 003.7 -3 784 560.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 004 331.7 -161 617.5 -196 255.2 -194 015.7
US
Abbvie Inc
NYSE:ABBV
386.7B USD 6.5 164.7 16 22.7
US
Amgen Inc
NASDAQ:AMGN
174B USD 4.8 24.8 18 18
US
Gilead Sciences Inc
NASDAQ:GILD
153.2B USD 5.3 18.9 12.7 12.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.2B USD 10 31.9 23.4 24.4
US
Epizyme Inc
F:EPE
94.1B EUR 2 071.8 -528.7 -575.7 -560.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.5B USD 5.6 17.4 16.6 18.8
AU
CSL Ltd
ASX:CSL
83.9B AUD 3.6 18.8 12.7 15.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
49.1B USD 15.3 1 127.9 152 184.4
P/S Multiple
Revenue Growth P/S to Growth
KR
M
MedPacto Inc
KOSDAQ:235980
Average P/S: 8 208 280.9
90.5
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
56 284 545.2
140%
402 032.5
FR
Pharnext SCA
OTC:PNEXF
34 004 331.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.5
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.8
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.3
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10
10%
1
US
E
Epizyme Inc
F:EPE
2 071.8
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
6%
0.9
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
15.3
46%
0.3
P/E Multiple
Earnings Growth PEG
KR
M
MedPacto Inc
KOSDAQ:235980
Average P/E: 200.6
Negative Multiple: -15.3 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 865 260.4 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 617.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
164.7
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.8
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.9
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.9
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -528.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.4
10%
1.7
AU
CSL Ltd
ASX:CSL
18.8
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 127.9
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
M
MedPacto Inc
KOSDAQ:235980
Average EV/EBITDA: 35.9
Negative Multiple: -12.4 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 793 003.7 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 255.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
18
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.4
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -575.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
11%
1.5
AU
CSL Ltd
ASX:CSL
12.7
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
152
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
M
MedPacto Inc
KOSDAQ:235980
Average EV/EBIT: 42.4
Negative Multiple: -11.4 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 784 560.6 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 015.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.7
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.4
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -560.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.8
13%
1.4
AU
CSL Ltd
ASX:CSL
15.8
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
184.4
N/A N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 309,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.